ArriVent BioPharma Q4 2024 Earnings Report

ArriVent BioPharma EPS Results

• Actual EPS: -$0.60
• Consensus EPS: -$0.78
• Beat/Miss: Beat by +$0.18
• One Year Ago EPS: N/A

ArriVent BioPharma Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

ArriVent BioPharma Announcement Details

• Quarter: Q4 2024
• Date: 3/3/2025
• Time: Before Market Opens
• Conference Call Date: Monday, March 3, 2025
• Conference Call Time: 7:00AM ET

ArriVent BioPharma (NASDAQ:AVBP) operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.